Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 11:51 PM
Ignite Modification Date:
2025-12-24 @ 11:51 PM
NCT ID:
NCT01109251
Eligibility Criteria:
Inclusion Criteria:
Patient male or female from 20 to 80 years old included.
* ischemic or haemorragic CVA or TIA necessiting an hospitalisation or a consultation in the neurolgy department, from more than 2 months.
* Pression ≥140/90 ou 130/80 (diabetic) during the post CVA consultation and a mean TAM ≥135/85 ou 125/75 (diabetic) = non controlled AHT OR Pression \< 140/90 ou 130/80 (diabetic) during the post CVA consultation and a mean TAM ≥ 135/85 ou 125/75 (diabetic) = masked AHT
* Patient agreed to participate to the study and having signed the informed consent from
Exclusion Criteria:
* malignant AHT necessiting the urgent and specialised caring
* Persistance of a carotids bilateral stenosis from more than 70%
* Severe Renal Insufficiency (Creatinin Clearance estimated by the formula MDRD \< 30 ml/mn)
* CVA with major sequelae which according the judgement of the investigator will not allow to realise TAM :
* Major Cognitive Troubles
* Severe motor Troubles
* Severe concomitant Pathology
* Patient not speaking and not understanding french.
* Contre-indications to the realisation of TAM :
* Cardiac Arythmy
* Obese Patients for which the circumference of the arm is \> 33 cm
* Patient refusing to go to the 3 months after hospitalisation follow up consultation.
* Patient with no identified generalist
* Patient refusing to sign the informed consent form.
* Absence of affiliation to a Social system.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
20 Years
Maximum Age:
80 Years
Study:
NCT01109251
Study Brief:
Protocol Section:
NCT01109251